Trial Profile
A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Cardiovascular disorders; Stroke; Transient ischaemic attacks
- Focus Registrational; Therapeutic Use
- Acronyms SOCRATES
- Sponsors AstraZeneca
- 19 Feb 2019 Results assessing the time to Loading Dose and Risk of Recurrent Events, published in the Stroke
- 18 Jun 2018 Results published in the Stroke
- 18 Jul 2017 Results of post hoc-exploratory analysis assessing efficacy of ticagrelor versus aspirin among patients with embolic stroke of unknown source, published in the Stroke Journal.